Archivio istituzionale della ricerca dell'Università degli Studi di Palermo
IRIS è il sistema di gestione integrata dei dati della ricerca (persone, pubblicazioni, progetti, attività) adottato dall’Università di Palermo, e ha lo scopo di raccogliere, conservare, documentare, e diffondere ad accesso aperto le informazioni relative alla produzione scientifica degli autori afferenti all’Ateneo.
EnglishUveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients.
Basile M.S., Mazzon E., Fagone P., Longo A., Russo A., Fallico M., et al. (2019). Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. FRONTIERS IN ONCOLOGY, 9, 1145.
| Data di pubblicazione: | 2019 |
| Titolo: | Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets |
| Autori: | |
| Citazione: | Basile M.S., Mazzon E., Fagone P., Longo A., Russo A., Fallico M., et al. (2019). Immunobiology of Uveal Melanoma: State of the Art and Therapeutic Targets. FRONTIERS IN ONCOLOGY, 9, 1145. |
| Rivista: | |
| Digital Object Identifier (DOI): | http://dx.doi.org/10.3389/fonc.2019.01145 |
| Abstract: | Uveal Melanoma (UM) represents the most common primary intraocular malignant tumor in adults. Although it originates from melanocytes as cutaneous melanoma, it shows significant clinical and biological differences with the latter, including high resistance to immune therapy. Indeed, UM can evade immune surveillance via multiple mechanisms, such as the expression of inhibitory checkpoints (e.g., PD-L1, CD47, CD200) and the production of IDO-1 and soluble FasL, among others. More in-depth understanding of these mechanisms will suggest potential targets for the design of novel and more effective management strategies for UM patients. |
| URL: | http://www.frontiersin.org/Oncology/about |
| Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| basile front oncol 2019 1.pdf | Post-print | Open Access Visualizza/Apri |
Copyright © 2020